A pioneering clinical study has found that delivering regenerative cells to fetuses diagnosed with spina bifida as part of a surgical repair may represent a "major milestone" in treating birth defects.
Trial Details and Safety
The US-based trial focused on six unborn babies with a severe neural tube defect. Medical teams placed placenta-derived mesenchymal stem cells on the exposed area of the baby's spinal cord while the defect was being closed.
Importantly, the cell therapy demonstrated a favorable safety profile. The study team reported that the treatment did not lead to cancerous growths, hinder surgical recovery, or block the correction of co-occurring hindbrain herniation.
Promising Outcomes
Imaging conducted after delivery confirmed a successful correction of Chiari malformation in every participant. This neurological improvement is strongly associated with enhanced physical outcomes.
"Should it enable additional babies able to walk who wouldn't have, then it would become the conventional approach," commented the principal investigator. "These findings are super exciting and open the door to a variety of prospective new treatments."
Future Implications and Hope
Commentators reviewing the findings have suggested that additional validation of these apparent benefits could herald a "new era" in prenatal intervention. The possibility of ameliorating neurological damage seen in utero is viewed as a paradigm-shifting aim.
Especially significant would be advancements for urogenital and gastrointestinal outcomes, which are typical difficulties for those diagnosed with this condition.
The Path Forward
Despite this being a first-in-human effort involved a limited number of patients, its confirmed tolerability and hopeful trends provide a strong foundation for larger, more comprehensive studies. The addition of cellular treatment with current in-utero repair procedures holds considerable promise for changing life trajectories for future generations with spina bifida.